StephenMatthewSchleicherMD

Oncology • Nashville, TN

Clinical Fellow in Medicine, Brigham and Women's Hospital

Join to view full profile

Dr. Schleicher is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Schleicher's full profile

Already have an account?

Office
2004 Hayes St
Ste 350
Nashville, TN 37203
Phone+1 615-312-3333

Fax+1 615-986-0560

Education & Training

Brigham and Women's HospitalResidency, Internal Medicine, 2011 - 2014
Vanderbilt University School of MedicineClass of 2011

Certifications & Licensure

AR State Medical License 2024 - 2026
NY State Medical License 2015 - 2026
TN State Medical License 2018 - 2026
KY State Medical License 2024 - 2025
MO State Medical License 2024 - 2025
MS State Medical License 2024 - 2025
AL State Medical License 2024 - 2024
MA State Medical License 2014 - 2015
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology
Join now to see all

Awards, Honors, & Recognition

Inductee Alpha Omega Alpha Honor Medical Society, 2011

Publications & Presentations

PubMed

64 citations
Akt and ERK1/2 pathways are components of the vasopressin signaling network in rat native IMCD
Trairak Pisitkun, Vinitha Jacob, Stephen M. Schleicher, Chung-Lin Chou, Ming-Jiun Yu
American Journal of Physiology. Renal Physiology. 2008-07-30
26 citations
Enhanced Radiosensitivity of Androgen-Resistant Prostate Cancer: AZD1152-Mediated Aurora Kinase B Inhibition
Kenneth J. Niermann, Luigi Moretti, Nicholas J. Giacalone, Yunguang Sun, Stephen M. Schleicher
Radiation Research. 2011-01-11
12 citations
A Novel Bioluminescence Orthotopic Mouse Model for Advanced Lung Cancer
Bo Li, Artour Torossian, Wenyan Li, Stephen M. Schleicher, Kathy Niu
Radiation Research. 2011-06-10

Lectures

The effect of guideline-concordant novel therapy use on meeting cost targets in OCM: Results from a large community oncology network.
ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019

Press Mentions

Consolidation Concerns: What Does $2.1 Billion OneOncology Deal Signal?May 2nd, 2023
The Enhanced Oncology Care Model and What It Means for Participating Oncology PracticesAugust 29th, 2022
Community Oncology Alliance Launches Oncology Fellows Task ForceMay 17th, 2022
Join now to see all

Professional Memberships